A Phase 2 Study of Lenvatinib Before Surgery in People with Thyroid Cancer


Full Title

A Phase 2 Study of Neoadjuvant Lenvatinib in Locally Advanced Invasive Thyroid Cancer


Lenvatinib is a medication used to treat thyroid cancer that has come back or spread to other parts of the body. It works by inhibiting the development of the blood vessels that tumors need to grow and spread.

In this study, researchers want to assess the safety and effectiveness of giving lenvatinib before surgery in people with locally advanced thyroid cancer (cancer which has spread beyond its original location) and can be surgically removed. It is hoped that presurgical lenvatinib will shrink thyroid tumors and improve outcomes for patients. Lenvatinib is taken orally (by mouth).

Who Can Join

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have locally advanced thyroid cancer that can be surgically removed.
  • Patients with medullary thyroid cancer or anaplastic (undifferentiated) thyroid cancer may not participate in this study.
  • Prior radiation therapy to the neck or previous lenvatinib therapy is not permitted.
  • Patients must be physically well enough that they are able to be mobile, take care of themselves, and engage in all but physically strenuous activities. For example, they must be well enough that they could carry out office work or light housework.
  • This study is for people age 18 and older.


For more information about this study and to ask about eligibility, please contact Dr. Richard Wong at 212-639-7638.




Phase II (phase 2)

Disease Status

Newly Diagnosed & Relapsed/Refractory




ClinicalTrials.gov ID